Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy
Vedolizumab had increased efficacy over placebo in CD patients irrespective of TNF-α antagonist treatment history.
Media formats available
Completing the pre-test is required to access this content.
Pre-Survey
Completing the pre-survey is required to access this content.